MMV 183
Alternative Names: MMV-183Latest Information Update: 08 Oct 2025
At a glance
- Originator Medicines for Malaria Venture; TROPIQ Health Sciences
- Class Antimalarials
- Mechanism of Action Acetate-CoA ligase inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Malaria
Most Recent Events
- 30 Jul 2025 Preclinical trials in Malaria (Prevention) in Switzerland (IM) before July 2025 (Medicines for Malaria Venture pipeline, July 2025)
- 30 Jul 2025 Preclinical trials in Malaria (Prevention) in Switzerland (IV) before July 2025 (Medicines for Malaria Venture pipeline, July 2025)
- 30 Jul 2025 Medicines for Malaria Venture plans a first in human clinical trial for Malaria (Prevetion) (Parenteral, Injection)(Medicines for Malaria Venture pipeline, July 2025)